• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿脓毒症:挑战与辅助治疗。

Pediatric sepsis: challenges and adjunctive therapies.

机构信息

Division of Critical Care Medicine, Cincinnati Children's Hospital Research Foundation, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.

出版信息

Crit Care Clin. 2013 Apr;29(2):203-22. doi: 10.1016/j.ccc.2012.11.003. Epub 2013 Jan 3.

DOI:10.1016/j.ccc.2012.11.003
PMID:23537672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3612267/
Abstract

Sepsis remains an important challenge in pediatric critical care medicine. This review provides an appraisal of adjunctive therapies for sepsis and highlights opportunities for meeting selected challenges in the field. Future clinical studies should address long-term and functional outcomes as well as acute outcomes. Potential adjunctive therapies such as corticosteroids, hemofiltration, hemoadsorption, and plasmapheresis may have important roles, but still require formal and more rigorous testing by way of clinical trials. Finally, the design of future clinical trials should consider novel approaches for stratifying outcome risks as a means of improving the risk-to-benefit ratio of experimental therapies.

摘要

脓毒症仍然是儿科重症监护医学的一个重要挑战。这篇综述评估了脓毒症的辅助治疗方法,并强调了该领域应对选定挑战的机会。未来的临床研究应关注长期和功能结果以及急性结果。皮质类固醇、血液滤过、血液吸附和血浆置换等潜在的辅助治疗方法可能具有重要作用,但仍需要通过临床试验进行正式和更严格的测试。最后,未来临床试验的设计应考虑分层结局风险的新方法,以提高实验治疗的风险效益比。

相似文献

1
Pediatric sepsis: challenges and adjunctive therapies.小儿脓毒症:挑战与辅助治疗。
Crit Care Clin. 2013 Apr;29(2):203-22. doi: 10.1016/j.ccc.2012.11.003. Epub 2013 Jan 3.
2
Effect of Extracorporeal Blood Purification on Mortality in Sepsis: A Meta-Analysis and Trial Sequential Analysis.体外血液净化对脓毒症死亡率的影响:一项荟萃分析和试验序贯分析
Blood Purif. 2021;50(4-5):462-472. doi: 10.1159/000510982. Epub 2020 Oct 28.
3
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.拯救脓毒症运动:严重脓毒症和脓毒性休克治疗国际指南:2008年版
Crit Care Med. 2008 Jan;36(1):296-327. doi: 10.1097/01.CCM.0000298158.12101.41.
4
Surviving sepsis campaign: research priorities for sepsis and septic shock.拯救脓毒症运动:脓毒症和脓毒性休克的研究重点。
Intensive Care Med. 2018 Sep;44(9):1400-1426. doi: 10.1007/s00134-018-5175-z. Epub 2018 Jul 3.
5
[THE NEW CONCEPT OF COMBINED USE OF EXTRACORPOREAL BLOOD CORRECTION IN COMPLEX INTENSIVE THERAPY OF SEVERE SEPSIS IN PATIENTS AFTER CARDIAC SURGERY].[体外血液净化联合应用在心脏手术后严重脓毒症患者综合强化治疗中的新概念]
Anesteziol Reanimatol. 2015 Sep-Oct;60(5):75-80.
6
Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock.拯救脓毒症运动:脓毒症和脓毒性休克的研究重点。
Crit Care Med. 2018 Aug;46(8):1334-1356. doi: 10.1097/CCM.0000000000003225.
7
[Methods of Molecular Transfusion in the Intensive Therapy of Critical States].[危重症强化治疗中的分子输血方法]
Vestn Ross Akad Med Nauk. 2016;71(4):281-7. doi: 10.15690/vramn680.
8
[Rapid identification of patients at risk].
Dtsch Med Wochenschr. 2016 Jul;141(15):1066. doi: 10.1055/s-0042-112161. Epub 2016 Jul 27.
9
[Sepsis: new findings and developments. Update 2016].[脓毒症:新发现与进展。2016年更新]
Dtsch Med Wochenschr. 2016 Sep;141(20):1455-1458. doi: 10.1055/s-0042-112089. Epub 2016 Oct 4.
10
Sepsis - What's new in 2019?脓毒症——2019年有哪些新进展?
Curr Opin Anaesthesiol. 2019 Apr;32(2):163-168. doi: 10.1097/ACO.0000000000000707.

引用本文的文献

1
Immunomodulation in Pediatric Sepsis: A Narrative Review.儿童脓毒症中的免疫调节:一篇叙述性综述
J Clin Med. 2025 Apr 25;14(9):2983. doi: 10.3390/jcm14092983.
2
Impact of CytoSorb and CKRT on hemodynamics in pediatric patients with septic shock: the PedCyto study.细胞吸附柱(CytoSorb)和连续性肾脏替代治疗(CKRT)对脓毒性休克患儿血流动力学的影响:PedCyto研究
Front Pediatr. 2023 Sep 15;11:1259384. doi: 10.3389/fped.2023.1259384. eCollection 2023.
3
Thrombocytopenia and Bloodstream Infection: Incidence and Implication on Length of Stay in the Pediatric Intensive Care Unit.血小板减少症与血流感染:儿科重症监护病房的发病率及其对住院时长的影响
J Pediatr Intensive Care. 2021 Jan 20;11(3):209-214. doi: 10.1055/s-0040-1722338. eCollection 2022 Sep.
4
Biomarker combinations in predicting sepsis in hospitalized children with fever.用于预测住院发热儿童脓毒症的生物标志物组合。
BMC Pediatr. 2022 May 12;22(1):272. doi: 10.1186/s12887-022-03285-3.
5
Barriers and Proposed Solutions to a Successful Implementation of Pediatric Sepsis Protocols.成功实施儿童脓毒症治疗方案的障碍及建议解决方案
Front Pediatr. 2021 Nov 10;9:755484. doi: 10.3389/fped.2021.755484. eCollection 2021.
6
Interventions for Pediatric Sepsis and Their Impact on Outcomes: A Brief Review.小儿脓毒症的干预措施及其对预后的影响:简要综述
Healthcare (Basel). 2018 Dec 28;7(1):2. doi: 10.3390/healthcare7010002.
7
Salivary biomarkers may measure stress responses in critically ill children.唾液生物标志物可能用于测量危重症儿童的应激反应。
SAGE Open Med. 2018 Sep 25;6:2050312118802452. doi: 10.1177/2050312118802452. eCollection 2018.
8
Hypofibrinogenemia Is Associated With Poor Outcome and Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in Pediatric Severe Sepsis.低纤维蛋白原血症与儿科严重脓毒症不良预后及噬血细胞性淋巴组织细胞增多症/巨噬细胞活化综合征相关。
Pediatr Crit Care Med. 2018 May;19(5):397-405. doi: 10.1097/PCC.0000000000001507.
9
Glucocorticoid Receptor Polymorphisms and Outcomes in Pediatric Septic Shock.糖皮质激素受体基因多态性与小儿感染性休克的预后
Pediatr Crit Care Med. 2017 Apr;18(4):299-303. doi: 10.1097/PCC.0000000000001058.
10
Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock.嗅觉介质蛋白4是脓毒症休克中致病性中性粒细胞亚群的候选标志物。
Crit Care Med. 2017 Apr;45(4):e426-e432. doi: 10.1097/CCM.0000000000002102.

本文引用的文献

1
The pediatric sepsis biomarker risk model.儿童脓毒症生物标志物风险模型。
Crit Care. 2012 Oct 1;16(5):R174. doi: 10.1186/cc11652.
2
How much fluid resuscitation is optimal in septic shock?脓毒性休克中最佳的液体复苏量是多少?
Crit Care. 2012 Aug 8;16(4):146. doi: 10.1186/cc11393.
3
Nonrenal indications for continuous renal replacement therapy: A report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group.非肾脏适应证连续肾脏替代治疗:来自前瞻性儿科连续肾脏替代治疗登记组的报告。
Pediatr Crit Care Med. 2012 Sep;13(5):e299-304. doi: 10.1097/PCC.0b013e31824fbd76.
4
The role of plasmapheresis in critical illness.血浆置换在危重病中的作用。
Crit Care Clin. 2012 Jul;28(3):453-68, vii. doi: 10.1016/j.ccc.2012.04.009.
5
Higher vs. lower fluid volume for septic shock: clinical characteristics and outcome in unselected patients in a prospective, multicenter cohort.脓毒性休克中较高与较低液体量:前瞻性多中心队列中未选择患者的临床特征与结局
Crit Care. 2012 May 8;16(3):R76. doi: 10.1186/cc11333.
6
High-volume hemofiltration in the intensive care unit: a blood purification therapy.高容量血液滤过在重症监护病房中的应用:一种血液净化治疗方法。
Anesthesiology. 2012 Jun;116(6):1377-87. doi: 10.1097/ALN.0b013e318256f0c0.
7
Genetics and genomics in pediatric septic shock.儿科感染性休克的遗传学和基因组学。
Crit Care Med. 2012 May;40(5):1618-26. doi: 10.1097/CCM.0b013e318246b546.
8
Clinical review: sepsis and septic shock--the potential of gene arrays.临床综述:脓毒症和感染性休克——基因芯片的潜力。
Crit Care. 2012 Feb 8;16(1):204. doi: 10.1186/cc10537.
9
A critique of fluid bolus resuscitation in severe sepsis.严重脓毒症中液体冲击疗法的评价。
Crit Care. 2012 Jan 25;16(1):302. doi: 10.1186/cc11154.
10
New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury.关于脓毒症急性肾损伤行血液滤过和杂合治疗的基本原理、治疗靶点和剂量的新见解。
Blood Purif. 2012;33(1-3):44-51. doi: 10.1159/000333837. Epub 2011 Dec 15.